C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.95% | -22.66% | 36.31% | -23.62% | 1.15% |
| Total Depreciation and Amortization | -27.72% | -5.61% | -6.96% | -25.20% | 34.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.37% | -33.54% | -72.21% | 170.92% | -4.66% |
| Change in Net Operating Assets | 310.99% | -23.81% | 58.32% | -321.19% | 152.45% |
| Cash from Operations | 94.74% | -35.22% | 29.04% | -158.83% | 63.78% |
| Capital Expenditure | 42.19% | -481.82% | 97.32% | -122.16% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -191.13% | 120.09% | -1,895.02% | -88.50% | 34.27% |
| Cash from Investing | -191.72% | 120.01% | -2,075.84% | -89.50% | 33.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,465.18% | -99.49% | 1,454.89% | -- | -- |
| Repurchase of Common Stock | 100.00% | -1,328.57% | 41.67% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 5,500.00% | -99.39% | -- | -100.00% |
| Cash from Financing | 7,199.78% | -99.61% | 1,426.72% | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 230.06% | -184.39% | 181.63% | -172.02% | 738.71% |